765 related articles for article (PubMed ID: 14633785)
41. Distinguishing primary and secondary translocations in multiple myeloma.
Gabrea A; Leif Bergsagel P; Michael Kuehl W
DNA Repair (Amst); 2006 Sep; 5(9-10):1225-33. PubMed ID: 16829212
[TBL] [Abstract][Full Text] [Related]
42. Intravenous melphalan, thalidomide and prednisone in refractory and relapsed multiple myeloma.
Palumbo A; Avonto I; Bruno B; Ambrosini MT; Bringhen S; Cavallo F; Falco P; Boccadoro M
Eur J Haematol; 2006 Apr; 76(4):273-7. PubMed ID: 16519697
[TBL] [Abstract][Full Text] [Related]
43. Treatment of multiple myeloma in the targeted therapy era.
Saad AA; Sharma M; Higa GM
Ann Pharmacother; 2009 Feb; 43(2):329-38. PubMed ID: 19193585
[TBL] [Abstract][Full Text] [Related]
44. Protein Expression for Novel Prognostic Markers (Cyclins D1, D2, D3, B1, B2, ITGβ7, FGFR3, PAX5) Correlate With Previously Reported Gene Expression Profile Patterns in Plasma Cell Myeloma.
Mansoor A; Akhter A; Pournazari P; Mahe E; Shariff S; Farooq F; Elyamany G; Shahbani-Rad MT; Rashid-Kolvear F
Appl Immunohistochem Mol Morphol; 2015; 23(5):327-33. PubMed ID: 25265432
[TBL] [Abstract][Full Text] [Related]
45. Thalidomide, dexamethasone, Doxil and Velcade (ThaDD-V) followed by consolidation/maintenance therapy in patients with relapsed-refractory multiple myeloma.
Offidani M; Corvatta L; Polloni C; Gentili S; Mele A; Rizzi R; Catarini M; Caraffa P; Samori A; Blasi N; Ferranti M; Malerba L; Brunori M; Leoni P
Ann Hematol; 2011 Dec; 90(12):1449-56. PubMed ID: 21437586
[TBL] [Abstract][Full Text] [Related]
46. Autologous transplantation in multiple myeloma: a GITMO retrospective analysis on 290 patients. Gruppo Italiano Trapianti di Midollo Osseo.
Majolino I; Vignetti M; Meloni G; Vegna ML; Scimè R; Tringali S; Amaddii G; Coser P; Tribalto M; Raimondi R; Bergonzi C; Sajeva MR; Sica S; Ferrando F; Messina G; Mandelli F
Haematologica; 1999 Sep; 84(9):844-52. PubMed ID: 10477460
[TBL] [Abstract][Full Text] [Related]
47. Allogeneic hematopoietic stem cell transplantation for multiple myeloma: curative but not the standard of care.
Koehne G; Giralt S
Curr Opin Oncol; 2012 Nov; 24(6):720-6. PubMed ID: 22960558
[TBL] [Abstract][Full Text] [Related]
48. Novel approaches in myeloma therapy.
Munshi NC; Barlogie B; Desikan KR; Wilson C
Semin Oncol; 1999 Oct; 26(5 Suppl 13):28-34. PubMed ID: 10528892
[TBL] [Abstract][Full Text] [Related]
49. Thalidomide effects in the post-transplantation setting in patients with multiple myeloma.
Santos ES; Goodman M; Byrnes JJ; Fernandez HF
Hematology; 2004 Feb; 9(1):35-9. PubMed ID: 14965866
[TBL] [Abstract][Full Text] [Related]
50. Maintenance therapy with thalidomide improves overall survival after autologous hematopoietic progenitor cell transplantation for multiple myeloma.
Brinker BT; Waller EK; Leong T; Heffner LT; Redei I; Langston AA; Lonial S
Cancer; 2006 May; 106(10):2171-80. PubMed ID: 16598756
[TBL] [Abstract][Full Text] [Related]
51. Osteoprotegerin is a soluble decoy receptor for tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand and can function as a paracrine survival factor for human myeloma cells.
Shipman CM; Croucher PI
Cancer Res; 2003 Mar; 63(5):912-6. PubMed ID: 12615702
[TBL] [Abstract][Full Text] [Related]
52. Critical roles for immunoglobulin translocations and cyclin D dysregulation in multiple myeloma.
Bergsagel PL; Kuehl WM
Immunol Rev; 2003 Aug; 194():96-104. PubMed ID: 12846810
[TBL] [Abstract][Full Text] [Related]
53. Non-myeloablative allogeneic peripheral stem cell transplantation for multiple myeloma.
Ma SY; Lie AK; Au WY; Chim CS; Kwong YL; Liang R
Hong Kong Med J; 2004 Apr; 10(2):77-83. PubMed ID: 15075426
[TBL] [Abstract][Full Text] [Related]
54. Thalidomide and hematopoietic-cell transplantation for multiple myeloma.
Barlogie B; Tricot G; Anaissie E; Shaughnessy J; Rasmussen E; van Rhee F; Fassas A; Zangari M; Hollmig K; Pineda-Roman M; Lee C; Talamo G; Thertulien R; Kiwan E; Krishna S; Fox M; Crowley J
N Engl J Med; 2006 Mar; 354(10):1021-30. PubMed ID: 16525139
[TBL] [Abstract][Full Text] [Related]
55. Therapy of relapsed and refractory multiple myeloma.
Moehler T; Goldschmidt H
Recent Results Cancer Res; 2011; 183():239-71. PubMed ID: 21509688
[TBL] [Abstract][Full Text] [Related]
56. Tailoring initial treatment for newly diagnosed, transplantation-eligible multiple myeloma.
Stadtmauer EA
Oncology (Williston Park); 2010 Mar; 24(3 Suppl 2):7-13. PubMed ID: 20518365
[TBL] [Abstract][Full Text] [Related]
57. Multiple myeloma: an old disease with new hope for the future.
Zaidi AA; Vesole DH
CA Cancer J Clin; 2001; 51(5):273-85; quiz 286-9. PubMed ID: 11577492
[TBL] [Abstract][Full Text] [Related]
58. Concomitant mobilization of plasma cells and hematopoietic progenitors into peripheral blood of patients with multiple myeloma.
Lemoli RM; Cavo M; Fortuna A
J Hematother; 1996 Aug; 5(4):339-49. PubMed ID: 8877709
[TBL] [Abstract][Full Text] [Related]
59. Insulin like growth factor binding protein 7 (IGFBP7) expression is linked to poor prognosis but may protect from bone disease in multiple myeloma.
Bolomsky A; Hose D; Schreder M; Seckinger A; Lipp S; Klein B; Heintel D; Ludwig H; Zojer N
J Hematol Oncol; 2015 Feb; 8():10. PubMed ID: 25887188
[TBL] [Abstract][Full Text] [Related]
60. Bortezomib, thalidomide, dexamethasone induction therapy followed by melphalan, prednisolone, thalidomide consolidation therapy as a first line of treatment for patients with multiple myeloma who are non-transplant candidates: results of the Korean Multiple Myeloma Working Party (KMMWP).
Eom HS; Kim YK; Chung JS; Kim K; Kim HJ; Kim HY; Jin JY; Do YR; Oh SJ; Suh C; Seong CM; Kim CS; Lee DS; Lee JH
Ann Hematol; 2010 May; 89(5):489-97. PubMed ID: 20012045
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]